Protalix BioTherapeutics, Inc. (DE) (PLX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to Protallix Biotherapeutics Full Year 2025 Financial Results and Business Update Conference Call. As a reminder, this call is being recorded. I will now turn the conference over to Mike Moyer, Managing Director of LifeSite Advisors and Investor Relations Representative for Protallix. Thank you. You may begin. Thank you, Operator, and welcome to the Portalix Biotherapeutics Full Year 2025 Financial Results and Business Update Conference Call. With me today are Dror Bashan, President and CEO, and also with Portalix, Gilad Mamlok, Senior Vice President and Chief Financial Officer. A press release announcing the financial results and business updates were issued this morning and are available now on the Portalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings released in the teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause the actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in Fatalex's filings with the Securities and Exchange Commission. I will now turn the call over to Mr. Bashan. Dror? Thank you, Mike. And thank you everyone for joining this call. Today's discussion will include our forward-looking financial outlook, which emphasizes the strength and durability of our business as we enter 2026. However, I want to first discuss our important recent news. As previously announced, the European Commission has approved the 2 mg per kg every four weeks dosing regimen for El Fabrio for adults living with Fabry disease who are stable with an enzyme repl...